News & Events

Rehovot, Israel Sept 20, 2021

Based of the satisfactory safety data of VIDAC VDA 1102 on selected patients, Vidac Pharma received authorization to widen the scope of the trial to CTCL whole spectrum of conditions.

“We are very satisfied with the results of the first step which on top of the safety results granted to our trial a dose ranging protocol authorization. This will allow us to speed up recruitment at Beilinson Hospital in Israel under the direction of Prof. Emilia Hodak and program a Phase 2B both in Israel and in Europe. In a pre-approval meeting the Austrian Health Authorities (AGES) found our planning satisfactory and recommended such an extension to the full spectrum” declared Dr. Max Herzberg, Vidac Pharma Chairman.

VDA 1102 disrupts the binding of Hexokinase 2 (HK2) which is over expressed in cancer cells and binds to the VDAC channel of mitochondria. This binding causes exagerated glycolysis and blocks apoptosis. The extremely specific displacement of HK2 brings back metabolism to that of a normal cell and corrects tumor microenvironment. The company sees this mechanism of “Toposteric Effect TM” as a novel target to create safer pharmacological entities.

About Vidac:

Vidac Pharma was founded in Israel in 2012 by Dr Max Herzberg and aims to develop anti-cancer drugs based on restoring normal cellular metabolism. Cancer cells are characterized by a high rate of glycolysis and by suppressed apoptosis (programmed death) both of which favorizes high cellular reproduction and Tumor formation.  Vidac’s platform technology restores normal glycolysis and triggers apoptosis in these malignant cells. As normal cells are not subject to overexpression of HK2 they are not affected by Vidac’s drugs. Vidac’s lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial in actinic keratosis (AK) under an IND from the FDA and is presently in a Phase 2a clinical trial in CTCL in Israel. The company’s strategic intellectual property portfolio covers broadly its general approach using the TopostericTM effect avoiding enzymatic cell mis-location.

For Further information about Vidac Pharma:
Max Herzberg, PhD. Active Chairman of the Board 
  
www.vidacpharma.com

Rehovot, Israel Sept 13, 2021

Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system developed by the company. The new compounds are hydrophilic and were developed to fit systemic use such as IV, IM and/or Per-Os use. “This is opening the way to explore possible treatment of solid tumors overexpressing HK2 such as Prostate, Pancreas and other critical Oncological conditions” said Dr Max Herzberg, Chairman of Vidac Pharma “We are now going to fully develop this new product with the aim of a first in man end of 2022”. The new Chemical entities covered by the US Patent have no relation with the VDA 1102 a Clinical stage proprietary molecule currently under Phase 2 for both Actinic Keratosis and Cutaneous T-Cell Lymphoma while working through the same mechanism i.e detachment of HK2 from the VDAC channel in Mitochondria thus stopping the hyper glycolysis characterizing Cancer (Warburg effect) and promoting immunological response of the tumor microenvironment. In view of the novelty of these new chemical entities and their possible use to fight cancer the Company is optimist in receiving worldwide coverage.

About Vidac:

Vidac Pharma was founded in Israel in 2012 by Dr Max Herzberg and aims to develop anti-cancer drugs based on restoring normal cellular metabolism. Cancer cells are characterized by a high rate of glycolysis and by suppressed apoptosis (programmed death) both of which favorizes high cellular reproduction and Tumor formation.  Vidac’s platform technology restores normal glycolysis and triggers apoptosis in these malignant cells. As normal cells are not subject to overexpression of HK2 they are not affected by Vidac’s drugs. Vidac’s lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial in actinic keratosis (AK) under an IND from the FDA and is presently in a Phase 2a clinical trial in CTCL in Israel. The company’s strategic intellectual property portfolio covers broadly its general approach using the TopostericTM effect avoiding enzymatic cell mis-location.

For Further information about Vidac Pharma:
Max Herzberg, PhD. Active Chairman of the Board 
  
www.vidacpharma.com

Jerusalem, Israel, February 09 2021 – Vidac Pharma Ltd announces inclusion of the first Patient in a Placebo controlled Phase II study in early forms of Cutaneous T-Cell Lymphoma treated with its first in class drug VDA 1102 . VDA 1102 disrupt the binding of the glycolytic enzyme HK2 over expressed in Cancer Cells from the VDAC channel. This causes returning of Apoptosis (programmed death) and cell environment and functions to normal behavior. VDA 1102 does not affect normal cells. This clinical trial takes place under the direction of Prof. Emilia Hodak, head of Dermatology at Rabin Center (Beilinson) in Petach Tikva. Israel.

About Vidac Pharma

Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.

For more information regarding Vidac Pharma, please visit www.vidacpharma.com.

Contact: Max Herzberg +972-54-425-7381  

###

More Press Releases

 

 

NESS-ZIONA, IsraelApril 19, 2021 /PRNewswire/ -- Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment.

Under the agreement, GEM commits to provide Vidac with a share subscription facility of up to EUR 20 million for a 36-month term following the public listing of the company shares on a European National Stock Exchange. Vidac will control the timing and maximum amount of drawdown under the facility and has no minimum drawdown obligation. Concurrent to the public listing of Vidac Shares, GEM will receive warrants to purchase shares of the company.

Subject to the funding becoming available, the proceeds will be used to further progress the clinical development of Vidac's lead product, VDA 1102, currently in Phase 2 clinical trials for the treatment of the pre-cancerous condition Actinic Keratosis (AK) and for Cutaneous T-Cell Lymphoma (CTCL) a rare type of Non-Hodgkin Lymphoma. Proceeds will also be used for developing additional products from the company's proprietary HK2-focused discovery platform. This platform is based on the novel paradigm that detachment of HK2, a key enzyme in cellular metabolism, from the VDAC mitochondrial channel restores normal metabolism in malignant cells, resulting in the elimination of tumors through apoptosis (Programed death)  without harming the surrounding normal cells.

"We are very pleased by the GEM commitment" said Max Herzberg PhD, founder and active chairman of Vidac. "This funding, and becoming a public entity, will help us to continue the development of drugs based on our novel anti-cancer paradigm of selectively restoring normal metabolism in malignant cells. These are presently being developed for skin related cancers, such as AK, CTCL and later squamous cell carcinoma (SCC), but are expected to fight solid tumors as well.  Unlike many of today's anti-cancer drugs, safety and tolerability of the new treatments are projected to be very good as normal cells are not affected by the new paradigm. "

About Vidac:

Vidac Pharma was founded in Israel in 2012 by Dr Max Herzberg and aims to develop anti-cancer drugs based on restoring normal cellular metabolism. Cancer cells are characterized by a high rate of glycolysis and by suppressed apoptosis (programmed death) both of which favorizes high cellular reproduction and Tumor formation.  Vidac's platform technology restores normal glycolysis and triggers apoptosis in these malignant cells. As normal cells are not subject to overexpression of HK2 they are not affected by Vidac's drugs. Vidac's lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial in actinic keratosis (AK) under an IND from the FDA and is presently in a Phase 2a clinical trial in CTCL in Israel. The company's strategic intellectual property portfolio covers broadly its general approach as well as its drug candidates.

About the GEM group:

Global Emerging Markets (GEM) is a 3.4 Billion $ alternative investment group with operations in ParisNew York and Los Angeles. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed 400 transactions in 70  countries. Each investment vehicle has different sets of operational concepts of risk adjusted return and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information : www.gemny.com

For Further information about Vidac Pharma:

Max Herzberg, PhD. Active Chairman of the Board 
  
www.vidacpharma.com

Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its latest article in the prestigious Journal of Investigative Dermatology (2018, vol 138:2635-2643), discussing the discovery of Vidac’s anti-cancer drug VDA-1102 and its pre-clinical characterization. This peer-reviewed article establishes that VDA-1102’s mechanism of action is blocking the ‘glycolysis metabolic program’ in cancer cells forcing them to undergo programmed cell death. This is supported by data from multiple laboratory systems as well as in vivo efficacy, and lack of local skin reactions, in a mouse model of UVB-induced skin cancer. VDA-1102 is now in phase 2b clinical development for treating an early form of skin cancer, known as actinic keratosis (AK) which can develop to invasive squamous cell carcinoma of the skin.

Link to the article: " A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses. "

About VDA-1102 ointment

VDA-1102 is a novel, potent selective allosteric modulator of HK2 detaching it from the mitochondria of cancer cells as well as certain immune cells. Exposure to VDA-1102 triggers apoptosis in cancer cells by detaching hexokinase 2 (HK2) from the mitochondria. The drug also leads to glycolysis inhibition, reduction of immunosuppression in the tumor microenvironment, and to stimulation of an anti-tumor immune response. The selective profile of VDA-1102, which targets malignant cells without affecting the surrounding healthy tissue, offers a broad therapeutic window. VDA-1102 is being developed as a topical ointment for treatment of actinic keratosis (AK) and other non-melanoma skin cancers. VDA-1102 ointment has successfully completed a Phase 2a proof-of-concept study in subjects with AK, demonstrating efficacy, safety, and excellent tolerability, and is now in Phase 2b trial. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors.

About Vidac Pharma

Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.

For more information regarding Vidac Pharma, please visit www.vidacpharma.com.

Contact: Shelly Majar +972-2-5952090  

###

 

pdfDownload PDF

More Press Releases